Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Amortizatization of Intangibles (2017 - 2025)

Sutro Biopharma's Amortizatization of Intangibles history spans 9 years, with the latest figure at $755000.0 for Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 72.01% year-over-year to $755000.0; the TTM value through Sep 2025 reached $4.4 million, down 60.45%, while the annual FY2024 figure was $9.7 million, 7.1% up from the prior year.
  • Amortizatization of Intangibles for Q3 2025 was $755000.0 at Sutro Biopharma, down from $1.0 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $3.1 million in Q4 2023 and bottomed at -$799000.0 in Q4 2021.
  • The 5-year median for Amortizatization of Intangibles is $1.1 million (2025), against an average of $1.0 million.
  • The largest annual shift saw Amortizatization of Intangibles plummeted 1309.76% in 2021 before it skyrocketed 2224.27% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$799000.0 in 2021, then skyrocketed by 246.93% to $1.2 million in 2022, then skyrocketed by 160.05% to $3.1 million in 2023, then plummeted by 49.59% to $1.5 million in 2024, then plummeted by 50.94% to $755000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Amortizatization of Intangibles are $755000.0 (Q3 2025), $1.0 million (Q2 2025), and $1.1 million (Q1 2025).